Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination
Alternate Titles(s): Vaccine‐generated Immunity in Ocrelizumab‐treated Patients: Longitudinal Assessments (VIOLA)
- Description
This is a prospective, two-year study of immunity against SARS-CoV-2 in multiple sclerosis patients receiving ocrelizumab (OCR) at the time of COVID vaccination. Researchers recruited 60 patients (aged 18-65) from the NYU MS Comprehensive Care Center in New York City and the Rocky Mountain MS Center at the University of Colorado Anschutz Medical Center in Aurora, CO. Participants provided blood samples within 26 weeks of receiving the first vaccine dose and then 4, 12, 24, and 48 weeks following the primary two-dose series, as well as at 4, 12, 24, and 28 weeks following an additional booster dose. Patients also completed structured interviews at each study visit that reviewed COVID-19 symptom history and test results, MS relapses, adverse events related to OCR, and any changes to medical history. Electronic medical records were reviewed at each visit.
The anonymized dataset includes the study visit on which the data was collected, date of sample collection, anti-Spike antibody levels, virus neutralization activity, T cell responses, number of previous infections, and whether the patient had received monoclonal antibodies. Aggregated demographic and clinical characteristics (age, gender, BMI, race and ethnicity, MS subtype and treatment information, EDSS score, number of COVID-relevant comorbidities, and COVID vaccine and infection history) are also reported.
- Timeframe
- 2021 - 2023
- Geographic Coverage
-
Colorado - AuroraNew York (State) - New York City
Access
- Restrictions
-
Free to All
- Instructions
- Anonymized data are available for download via PubMed Central in Table S2.